Floatz logo

cd24 extracellular domain-igg1 fc domain recombinant fusion protein cd24fc

Acute Graft Versus Host Disease

Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)protein_peptidePhase 3Dormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Acute Graft Versus Host Disease cohort.

Asset / SponsorPhaseRating
METHOTREXATE
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 4BB
Basiliximab
Zhongming Zhang
Phase 4BB
TACROLIMUS
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 4BB
Ruxolitinib
Xenikos
Phase 3B
Lactobacillus Plantarum Strain 299V
Children's Oncology Group
Phase 3B

View all 14 →

Same molecule, other indications

cd24 extracellular domain-igg1 fc domain recombinant fusion protein cd24fc is also rated in:

acute myeloid leukemiaDormant
D
Indicative ·
30 / 100
View asset →
acute lymphoblastic leukemiaDormant
D
Indicative ·
30 / 100
View asset →
disease related to hematopoietic stem cell transplantDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →